Innovating Works

FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS

Activa
Mostrando 1 al 20 de 51 resultados
Adaptmet: Deconstructing adaptive evolution of metastasis Adaptmet aims to develop an advanced training program encompassing the multifaceted aspects of metastasis adaptation mechanisms, intending t...
2024-07-05 - 2029-02-28 | Financiado
NUCLEAR: METABOLIC REGULATION OF GENOME FUNCTION AND CELL IDENTITY FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: NUCLEAR aims at educating future experts that can drive the emerging field of Metabolic Regulation of Genome Function and Cell Identity rele...
2024-06-25 - 2029-02-28 | Financiado
CARLY: Development and characterization of a novel CAR T-cell therapy for NHL FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: HORIZON-MSCA-2023-PF-01 Non-Hodgkin lymphomas (NHL) are a group of blood cancers characterized by the expansion of malignant B lymphocytes creating tumors throughou...
2024-03-26 - 2027-06-30 | Financiado
FUN-HSC: TACKLING FUNCTIONAL MATURATION FOR TRANSPLANTABLE HEMATOPOIETIC STEM CELL GENERATION FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: ERC-2022-COG Hematopoietic stem cells (HSC) provide a lifelong supply of blood and immune cells. They are a life-saving therapy for leukemia and have rec...
2023-11-15 - 2028-12-31 | Financiado
IRB-TARGET: IRB Barcelona International PhD programme on TARGET for high impact biomedicine FUNDACIO INSTITUT DE RECERCA BIOMEDICA IRB BARCELONA tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-COFUND-01 IRB Barcelona (IRB) is an independent, non-profit research centre engaged in basic and applied biomedical science. The IRB-TARGET doctoral p...
2023-09-13 - 2029-08-31 | Financiado
BiTE-CAR: CD22/CD19 dual redirection Dual targeting of CD22 and CD19 with BiTE-secreting and CAR-expressing bi... FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: ERC-2022-POC2 Anti-CD19 immunotherapies based on Bi-specific T-cell Engagers (BiTE) or chimeric antigen receptor (CAR)-expressing T-cells have revolutioni...
2023-04-05 - 2024-12-31 | Financiado
ChroMet: Elucidating the role of macroH2A1.2 histone variant as a metabolic sensor in the epigenetic regulati... FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: HORIZON-MSCA-2022-PF-01 The initiation and maintenance of leukaemia are often regulated through the interaction of epigenetic mechanisms and metabolism, but how the...
2023-03-21 - 2026-07-31 | Financiado
CARxALL: Next generation, off-the-shelf, non fratricide-directed, CAR immunotherapy for relapse/refractory T-... ONECHAIN IMMUNOTHERAPEUTICS SL tramitó un HORIZON EUROPE: HORIZON-EIC-2022-TRANSITION-01 R/R T-ALL remains a major clinical challenge. Despite improved survival rates thanks to intensive chemotherapy regimens, event-free (EFS) an...
2023-03-13 - 2026-03-31 | Financiado
SECURED: Scaling Up secure Processing, Anonymization and generation of Health Data for EU cross border collab... UNIVERSITEIT VAN AMSTERDAM tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-IND-13 The overall goal of the SECURED project is to scale up multiparty computation, data anonymization and synthetic data generation, by increasi...
2022-11-23 - 2025-12-31 | Financiado
Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network PRINSES MAXIMA CENTRUM VOOR KINDERONCOLOGIE BV tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2022-10-10 - 2027-12-31 | Financiado
StemLinc: Identification and characterization of long non-coding RNAs as drivers of stemness in hematopoietic... FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Hematopoietic stem cells (HSCs) are a unique population defined by their self-renewal capacity and the potential to give rise to all blood l...
2022-07-13 - 2024-12-31 | Financiado
SIRT7-LC: Role of the SIRT7-NPM-c-Myc pathway in lung cancer FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Lung cancer is the second cause of death due to malignancy and diagnosed patients rarely survive beyond two years. Thus, unveiling the molec...
2022-06-29 - 2025-08-31 | Financiado
ALERT: Contribution of Lipid Droplets to the pathogenesis and chemoresistance of Acute Myeloid Leukemia FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERAS tramitó un HORIZON EUROPE: HORIZON-MSCA-2021-PF-01 Acute Myeloid Leukemia (AML) results from the uncontrolled expansion of differentiation-defective hematopoietic stem/progenitor cells or imm...
2022-06-27 - 2026-02-28 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.